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Main limitation of this metanalysis is the extreme variability of the included studies FU and bleeding definition, this partially invalidate the authors results. This is demonstrated by the big confidence interval of their results.
To avoid this problem, the authors should assess several sub analysis to "cleen" the data, otherwise I think that in the this form the results are not clinically relevant Major Comments 1) Different FU, to my opinion the authors should: -maybe exclude studies with FU < 6 months (at least <3 months), -assess a metaregression to evaluate the impact of FU on bleeding rate, -assess a subanalysis evaluating data <12 months, 12 months and > 12 months. 2) Assess a metaregression or a sub analysis regarding the discharge therapy, antiaggregant or anticoagulant 3) Different bleeding definition, please assess a sub analysis regarding just major bleeding incidence rate and clinical impact 4) Assess metaregression for main clinical features (sex, age…) 5) Please report forrest plost and funnel plot Minor Comments 1) Please report data as percentage, is more difficult for the reader
REVIEWER
Ariza Sole Bellvitge University Hospital Barcelona, Spain REVIEW RETURNED 17-Jul-2018
GENERAL COMMENTS
Interesting paper about a poorly studied and clinically relevant scenario The data are well presented and the conlcusions are justified by the findings The limitations stated by the authors are unavoidable I only suggest to inlcude one paper (n=1375, 69 bleeding episoses after ACS at mid term) Garay A, Ariza-Solé A, Abu-Assi E, Lorente V, Sánchez-Salado JC, Cequier Á. Mid Term Bleeding Risk Prediction After an Acute Coronary Syndrome: An Unsolved Question. Rev Esp Cardiol (Engl Ed). 2016 May;69(5):527-9. On the other hand, the important BleeMACS registry was published after the period of selection of studies, so this will change the selection criteria and I understand that this is not necessary. However, given the importance of this study (more than 15000 patients form several conutries across the world) I suggest t comment as a separate study in the discussion
REVIEWER

Javier Valle
Eastern Colorado Health Care System, Denver, CO, USA REVIEW RETURNED 29-Jul-2018
GENERAL COMMENTS
In this analysis, the authors perform a narrative systematic review of post-discharge bleeding after hospitalization for acute coronary syndromes, using randomized clinical trials and observational analyses to compose their findings. The authors found an incidence of post-discharge bleeding ranging from 2.0-375 events per 1000 persons at 12 months in observational cohorts, and between 9.6 and 394 per 1000 persons in randomized cohorts. They were unable to draw conclusions on an association between mortality, MACE or rehospitalization with post-discharge bleeding due to a lack in strength of evidence.
The authors are to be commended for their efforts in synthesizing a broad and challenging set of studies for an understudied topic.
Comments: 1. The authors persistently refer to the "primary care setting" which can be misleading or confusing to the reader. The context for these bleeding events should be called the "outpatient" setting, as bleeding issues can be discovered at any outpatient evaluation (emergency, urgent care, subspecialty appointments) 2. The authors investigated post-discharge bleeding amongst patients with acute coronary syndromes, but did not specify the method of treatment for ACS-PCI only is implied, but medical therapy would be included by their definitions and inclusions. This heterogeneous population should be better defined for the reader.
If medical therapy/lytics were included that could potentially significantly impact the findings. Both indication and treatment should factor into the defined group for analysis, or at least be used to stratify. e. Discussion, "we report that the incidence of these bleeds was highest in the initial three months… but continued to increase" -sentence implies the incidence continues to escalate over time. Understand authors' intent, but perhaps the frequency is highest in the first 3 months, with continued events after? Or something to differentiate the high incidence in the 1st three months, followed by continuing events.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 Ismail and colleagues has produced a review paper with the Title: Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within the primary care setting: A systematic review. The purpose was to examine the incidence and prognostic impacts of bleeding complications after an acute coronary syndrome. In addition, the authors wanted to determine the association of post-discharge bleeds with mortality, major adverse cardiovascular events (MACE), re-hospitalization and re-infarction. The review included both observational studies and RCT's. The criteria for selecting the studies are well-described and Quality assessment scales were used for both types. The populations and designs of the studies were heterogeneous. So were the definitions of bleedings, length of follow-up, and information of used antithrombotic medication. The authors have shown this diversity of the studies in large tables. In addition, large tables have been generated to describe bleeding rates, timing and type of bleeding. At last the authors present a relevant discussion of the subject including mentioning of its limitations, illustrating a good overview of the complexity of the subject.
We thank reviewer 1 for their positive comments and for taking the time to peer review our manuscript.
Reviewer 2 The article is well written, however have to be improved. Main limitation of this metanalysis is the extreme variability of the included studies FU and bleeding definition, this partially invalidate the authors results. This is demonstrated by the big confidence interval of their results. To avoid this problem, the authors should assess several sub analysis to "clean" the data, otherwise I think that in the this form the results are not clinically relevant.
We thank the reviewer for taking the time to review our manuscript and for providing constructive comments to improve the paper. We agree with the reviewer that there is marked variability in the reporting of both bleeding events and outcomes in the included studies. This is because many of the studies have been undertaken using electronic healthcare records and so the definitions of major bleeding are clinical definitions rather than standardised definitions as used in, for example, randomised trials to define bleeding events. Furthermore, the bleeding risk profile of cohorts will vary (based on their demographics, treatments etc) which will impact on the reported rates post discharge that will also contribute to further heterogeneity. Nevertheless, with these limitations in mind, the review is the first to study the incidence, timing, and types of post-discharge bleeding complications, and their association with mortality, MACE, re-infarction and re-hospitalisation using data from over 700,000 participants and so represents an important contribution to the literature.
Major Comments: 1) Different FU, to my opinion the authors should: -maybe exclude studies with FU < 6 months (at least <3 months), -assess a metaregression to evaluate the impact of FU on bleeding rate, -assess a subanalysis evaluating data <12 months, 12 months and > 12 months.
We thank the reviewer for this suggestion. We had considered this approach, but because different definitions of major bleeding are used, the rates vary significantly even with the approach suggested by the reviewer. We had previously undertaken a meta-analysis at the different time points, but the I2 values were between 95% and 100%, and therefore it would not be considered best practice to pool data with such heterogeneity. Therefore, the narrative synthesis approach was adopted. Nevertheless, to ensure ease of interpretation, all studies included in the review are presented by length of follow-up and bleeding definition as in Tables 2, 3 , and 4 to give the reader an overview of the variation in bleeding rate.
2) Assess a metaregression or a sub analysis regarding the discharge therapy, antiaggregant or anticoagulant
We thank the reviewer for this suggestion. We have presented the incidence of bleeding stratified by both type and duration of discharge antithrombotic therapy (in studies that specified these) in supplementary tables 3 for observational studies and table 4 for RCTs. Results are presented by length of follow-up.
3) Different bleeding definition, please assess a sub analysis regarding just major bleeding incidence rate and clinical impact
We thank you for this suggestion. The incidence of bleeding stratified by bleeding severity (major, minor and nuisance bleed) is presented in supplementary table 7 (in studies that specified these) and reported in the text on p.16. The clinical impact of bleeding is also reported based on length of followup and severity of bleed in table 4.
4) Assess metaregression for main clinical features (sex, age…)
Unfortunately, we were unable to stratify by age and gender due to selective reporting by studies included in the review. The majority of studies did not report on episodes of bleeding by age or gender.
5) Please report forrest plots and funnel plot
Due to the wide variability between studies, with I2 values between 95% and 100% we were unable to carry out a meta-analysis and this has been reported as a limitation in the review. Please see response to comment 1. Thank you, the paper has now been included in review 2) On the other hand, the important BleeMACS registry was published after the period of selection of studies, so this will change the selection criteria and I understand that this is not necessary. However, given the importance of this study (more than 15000 patients form several countries across the world) I suggest to comment as a separate study in the discussion
The literature search has been updated to include studies published up to August 2018. The BleeMACS registry study Garay et al., 2018 is now included in the review and the BleeMACS score has been mentioned in the discussion.
Reviewer 4
In this analysis, the authors perform a narrative systematic review of post-discharge bleeding after hospitalization for acute coronary syndromes, using randomized clinical trials and observational analyses to compose their findings. The authors found an incidence of post-discharge bleeding ranging from 2.0-375 events per 1000 persons at 12 months in observational cohorts, and between 9.6 and 394 per 1000 persons in randomized cohorts. They were unable to draw conclusions on an association between mortality, MACE or rehospitalization with post-discharge bleeding due to a lack in strength of evidence. The authors are to be commended for their efforts in synthesizing a broad and challenging set of studies for an understudied topic.
We thank reviewer 4 for taking the time to review our manuscript and for their constructive comments during the review process.
Comments:
1) The authors persistently refer to the "primary care setting" which can be misleading or confusing to the reader. The context for these bleeding events should be called the "outpatient" setting, as bleeding issues can be discovered at any outpatient evaluation (emergency, urgent care, subspecialty appointments)
In retrospect, we agree with the reviewer. We have amended the text to refer to the outpatient setting and this has been changed throughout the manuscript.
2) The authors investigated post-discharge bleeding amongst patients with acute coronary syndromes, but did not specify the method of treatment for ACS-PCI only is implied, but medical therapy would be included by their definitions and inclusions. This heterogeneous population should be better defined for the reader. If medical therapy/lytics were included that could potentially significantly impact the findings. Both indication and treatment should factor into the defined group for analysis, or at least be used to stratify.
We thank the reviewer for these suggestions. We have now stratified the incidence of bleeding by ACS indication (STEMI, NSTEMI/UA) and ACS management strategy in studies that specified these. The results are reported under the heading "incidence of bleeding" and in supplementary tables 5 and 6.
3) Confining the population to an ACS population is an interesting choice. Would it be to specifically define the presumed highest risk population for bleeding? If so, it would be helpful to have a comparator group (stable angina, elective PCI) to assess just how much higher/different the risk of post-discharge bleeding could be.
Our focus was to summarise the overall incidence of bleeding post ACS post hospital discharge as this is a major area of clinical interest currently, as the reviewer, an expert in the field, will appreciate. This work also serves as a background to analysis of primary care data derived from a national general practice database that focuses on this theme. The problem with a comparator group is that the patient cohorts would be very different and so any comparison of bleeding events meaningless. For example, patients with stable angina will only be prescribed a single antiplatelet therapy (aspirin) whilst those that undergo elective PCI will often be a much more selected cohort than patients with ACS (who may not always have a PCI), and will be prescribed less potent anti-platelet agents (clopidogrel rather than prasugrel or ticagrelor, or GPIIb/IIIa inhibitors). Given the limited data on post discharge bleeding events in ACS, our motivation was to provide an overview of the incidence, timing and types of post-hospital discharge bleeds within the adult post-ACS population.
4) It is unclear to me that the authors included all studies assessing their specific question. For example, Valle et al (Circ Interventions 2016) assessed post-discharge bleeding among post-PCI patients and broke down bleeding into ACS and non-ACS indications for PCI, but was not included in the analysis. A better description of their search methodology and rationale for their choices would be helpful.
The Valle et al., 2016 study was a very well conducted and important study. Whilst the percentage of ACS patients with bleeding was provided, we were unable to extract associated 95% confidence interval nor were we able to extract crude numbers of patients with bleeding to calculate this. This exclusion criterion is mentioned in Table 1. 5) It is unclear the reasons for concluding the analysis at 2016 studies. Given the narrative form of this review, it would be reasonable to include 2017 at the minimum.
We agree with the reviewer and have updated the literature search to include studies published up to August 2018.
6) The authors include clinical trials and substudies (post-hoc analyses, registry analyses) of the same trials, concerning for significant subject overlap. The authors suggest that a total of 870,785 patients comprised their analytic cohort, however with the aforementioned overlap it is unclear if these represent UNIQUE subjects. While the narrative review relieves some of the issues that this would raise for a more comprehensive meta-analysis, this possible undefined overlap still raises questions for the reader with regards to interpretation of their findings. Furthermore, the results section references a different number (761,997) as their overall cohort.
We thank the reviewer for raising this point and agree that it can be confusing for the reader. For studies using the same data source, we have made amendments for the primary objective (incidence of bleeding) by only including one study in the review, based on: 1) quality, and then by 2) sample size, followed by 3) length of follow-up, unless the studies reported on different outcomes (this is mentioned under "eligibility criteria"). The 761, 997 was the overall number of participants from studies that reported on the incidence of bleeding (i.e. excluding studies that only reported on the secondary outcomes of mortality, MACE and rehospitalisation), but this has changed since updating the literature search and has been broken down into overall number of participants for the primary and separately for the secondary objectives. This has been amended all through the manuscript.
7) While the authors do separate the types of bleeding by BARC category (when possible), their reported overall numbers and incidences of bleeding include higher rates from bruising/ecchymosis. This may be misleading given the clear clinical difference between nuisance bleeding and bleeding requiring hospitalization. Would recommend making a stronger/clearer distinction between these types.
Thank you for the suggestion. The overall incidence of bleeding stratified by bleeding severity (major, minor and nuisance bleed) has been amended and is presented in supplementary table 7 as per reviewers suggestion. Results are presented by length of follow-up and then bleeding definition in studies that specified these. This has also been reported in the manuscript under "incidence of bleeding" as well as in the discussion.
8) Minor comments:
a. Table 1 is missing a bullet point in the "secondary objective" heading-for the "evaluated outcome of or composite of mortality…" inclusion Thank you, this has now been added b. Under results-the first sentence appears to imply that the 33 studies are comprised of JACC, Web of science, and bibliography searches. Referring to the 33 studies as derived from the EMBASE search would be helpful for clarity.
We have now amended this.
c. Results, Bleeding and risk of mortality-this paragraph is unclear and could benefit from reformatting of the 2nd sentence.
The sentence has been restructured to "The risk of mortality with bleeding was higher in a study that measured bleeding based on BARC 2 and 3 criteria, but lower in a study that defined bleeding as events leading to death or re-hospitalisation".
d. Results, Bleeding and risk of MACE-Would be helpful to understand which kind of bleeding (severity/type) was included in these analyses.
Thank you for this suggestion, the bleeding definition used in these studies has been added to the results section e. Discussion, "we report that the incidence of these bleeds was highest in the initial three months… but continued to increase" -sentence implies the incidence continues to escalate over time. Understand authors' intent, but perhaps the frequency is highest in the first 3 months, with continued events after? Or something to differentiate the high incidence in the 1st three months, followed by continuing events.
Thank you, the sentence has been reformatted to "We report that the incidence of these bleeds was highest in the initial three months after hospital discharge for ACS, with bleeding events continuing to occur even after 1 year"
VERSION 2 -REVIEW
REVIEWER
Rikke Sørensen
Copenhagen University Hospital Rigshospitalet, Department of Cardiology, Blegdamsvej 9, 2100 København Ø REVIEW RETURNED 02-Oct-2018
GENERAL COMMENTS
The manuscript has been relevantly improved, and it is recommended that it should be accepted for publication.
REVIEWER
Mario Iannaccone SS. Annunziata Savigliano ASL CN1 and University of Turin, Italy REVIEW RETURNED 13-Oct-2018
GENERAL COMMENTS
In this paper Dr Ismail et al evaluate the incidence of bleeding events post-acute coronary syndrome (ACS) following hospital discharge. Randomised controlled trials (RCT) and observational studies reporting on the incidence of bleeding post-hospital discharge were included in this review.
The authors should be congratulated for their effort, they revised a big amount of that, with a real capillary research and classification of all the results. Further the paper is well written.
However unfortunately this big amount of that is really confusing, the result section is a little bit long and the most clinical important results are not easily deducible. It is really difficult for the reader to understand if the authors addressed some kind of meta-analytic analysis, as example the report in the discussion section "Our analysis suggests that nuisance bleeding events post hospital discharge were not associated with mortality, but minor and major bleeding events may increase the risk of mortality, although the SOE was rated as low and only six studies reported on this outcome, three of which were conducted on a Danish population", this kind of sentences can confuse the reader.
Specific Comments: -Results section should be shortened, in particular move the single study differences in the discussion section, leave the main finding in the result section -Try to highlight the most clinical finding in the results and discussion section, in particular major bleeding and the impact of these on MACE -Remove of the misleading sentences regarding a meta-analytic calculation (despite this project is recorded on PROSPERO as a review and metanalysis, this paper is presented as review only)
REVIEWER
Javier Valle
Rocky Mountain VA Medical Center, Aurora, CO, USA REVIEW RETURNED 18-Oct-2018
GENERAL COMMENTS
In this analysis, Nafiu et al performed a systematic review and meta-analysis evaluating the incidence and severity of postdischarge bleeding among patients suffering ACS, and the association of such bleeding events with longitudinal events of mortality and MACE. Incorporating retrospective, observational analyses and randomized clinical trials, the authors analyzed 714,000 patients, finding widely ranging reported incidences of bleeding, and varying associated longitudinal outcomes. While the authors are to be commended for their efforts, I unfortunately have concerns over the overall heterogeneity of their population. Multiple patient cohorts, with high heterogeneity of management for ACS and follow-up, as well as bleeding definitions. While raised in their limitations, the overall heterogeneity of the analytic cohort significantly muddies the discernable results from the analysis. In order to solidify the interpretation of the reported findings, the authors should consider breaking down their cohort to similar treatment arms (i.e. post-PCI, DAPT) and with similar bleeding definitions (BARC or TIMI). Otherwise, there are significant concerns about the external validity of their reported findings, as while the cohort is comprised of post-ACS patient, it is challenging as a clinician to extrapolate these findings to specific patient groups given the heterogeneity of the included analyses. As a minor comment, it would be helpful for the authors to include figures depicting the incidence of bleeding or perhaps demonstrating the identified associations with outcomes. The tables are quite detailed, and it may help the reader condense the results into a more digestible form.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 1
We thank reviewer 1 for taking time to peer review our manuscript and for the positive feedback once again. We thank reviewer 2 once again for the constructive feedback and comments. In retrospect, we agree with the reviewer that the result section could have been more succinct. We have now trimmed down the result section by shortening text and only reporting the most relevant findings. Other results such as the incidence of bleeding stratified by ACS presentation and discharge drug combination and duration has been moved to the appendix and the reader has been referred to these results in the supplementary appendix. We have also revised the sentence in the discussion to "Our review shows that major bleeding may increase the risk of mortality by nearly threefold in the first 12 months after hospital discharge, but the strength of the evidence was weak".
Reviewer
Specific Comments:
Results section should be shortened, in particular move the single study differences in the discussion section, leave the main finding in the result section Thank you, we have reduced the result section by only reporting the most relevant findings from the review and referred the reader to the appendix for further information.
Try to highlight the most clinical finding in the results and discussion section, in particular major bleeding and the impact of these on MACE Thank you, we have reformatted the result and discussion section and only included key findings from the review with particular emphasis on major bleeding events.
-
Remove of the misleading sentences regarding a meta-analytic calculation (despite this
project is recorded on PROSPERO as a review and metanalysis, this paper is presented as review only)
We thank the reviewer for this recommendation. Any text which may mislead the reader into thinking the study was a meta-analysis has been removed throughout the manuscript. it is challenging as a clinician to extrapolate these findings to specific patient groups given the heterogeneity of the included analyses.
Reviewer
Whilst there was the issue of selective reporting by authors, we have been able to report the incidence of bleeding stratified by discharge antithrombotic drug combinations and duration (whether SAPT, DAPT and receipt of oral anticoagulants), ACS presentation (whether STEMI, NSTEMI/UA) and inhospital management strategy (whether medically managed or with PCI) in studies that specified these as per the reviewer's suggestion. These incidences are reported in tables 2, 3 and supplementary tables 3, 4 and 5 in order of the same length of follow-up and definition of bleeding used. The reader can extrapolate these findings to the relevant post ACS population while also being able to assimilate the variation between studies.
